Inhibitory effect of PD173074 drug on DMBA-induced mammary carcinoma in female Swiss albino mice.

Alghamdi, Abeer S.; Alobaid, Hussah M.; Rady, Ahmed M.; AL-Qahtani, Badr Abdullah Aldahmash Wejdan S.; Alqarni, Aisha H.; Almalki, Samiah A.; Elnagar, Doaa M.

Purpose: To determine the effect of PD173074 on mammary carcinoma. Methods: Virgin female mice were randomly divided into 4 groups of 10 mice per group. Group 1 (control) received clean water, group 2 received an oral dose of 50 mg/kg PD173074 twice a week, group 3 received a single dose of 50 mg/kg 7,12-Dimethylbenz(a)anthracene (DMBA) in the breast for carcinoma induction, group 4 received DMBA and after that treated with PD173074 one week later for 4 weeks. Hormonal analysis, oxidative stress, levels of cytokines IL6 and TNF-α, and histopathological and immunohistochemical analysis were carried out. Results: Treatment with PD173074 significantly lowered estrogen, progesterone, oxidative stress indices, cytokines IL6, and TNF-α levels (p < 0.05) raised due to carcinoma induction. Pyrido (2,3-d) pyrimidine derivative PD173074 lowered the Nottingham histopathological score and reduced the incidence of invasive ductal carcinoma. Furthermore, immunohistochemical analysis showed that posttreatment with PD173074 significantly decreased K167 expression (p < 0.05). Conclusion: PD173074 significantly reduces estrogen, progesterone, oxidative stress indices, cytokines, TNF-α, Nottingham histopathological score, and KI-67 expression. Additional studies would be required to validate the actual mechanisms of this drug action.

IMMUNOHISTOCHEMISTRY; LABORATORY mice; DUCTAL carcinoma; OXIDATIVE stress; PYRIMIDINE derivatives; BREAST

Tropical Journal of Pharmaceutical Research, 2024, Vol 23, Issue 12, p1983

1596-5996

Academic Journal

10.4314/tjpr.v23i12.3